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ABSTRACT  
Background: Polycystic ovarian syndrome (PCOS) is the multisystemic disorder 
and most common reproductive endocrinopathy of women during their 
characterized by a varied and often complex array of metabolic and endocrine 
abnormalities, including hyperinsulinaemia, hyperglycaemia, glucose intolerance 
and obesity which put women with PCOS at a higher risk for diabetes, 
hypertension, dyslipidemia, and cardiovascular disease. Objectives: To estimate 
Fasting blood glucose and lipid profile in women with PCOS and normal females. 
Materials and Methods: After Ethical Committee Approval, blood samples were 
collected from 50 diagnosed PCOS cases and 50 healthy controls (premenopausal 
women); aged 18 to 40 years. Fasting plasma glucose and lipid profile were 
investigated in both PCOS patients and controls. The correlation between these 
biochemical parameters were then studied in the PCOS group. Data analysis done 
using studentʽ t’ test.  Result: There was a significant increase in fasting plasma 
glucose levels in PCOS patients as compared to controls. PCOS women had higher 
BMI with increased total cholesterol, TGL, LDL-C, VLDL-C and lower HDL-C (P < 
0.05) as compared to the controls which was statistically significant. The levels of 
glucose showed significant positive correlation with total cholesterol(P<0.01), 
triglycerides(P<0.05), LDL-C (P<0.01) whereas non-significant negative correlation 
with HDL-C. Conclusion: The findings of this study confirms the association 
between Glucose, BMI and dyslipidaemia in PCOS and may help to identify 
women with PCOS at risk of cardio metabolic syndrome thereby confirming the 
association between PCOS and cardiovascular risk factors. 
Keywords: Polycystic Ovarian Syndrome, Dyslipidaemia, Cardio Metabolic 
Syndrome, Insulin Resistance.
 
INTRODUCTION 
Polycystic ovarian syndrome (PCOS) is the multisystem 
reproductive endocrinopathy with ovarian expression 
of metabolic disturbances and a wide spectrum of 
clinical features characterized by increased ovarian and 
adrenal androgen secretion, hyperandrogenic 
metabolic syndrome symptoms such as hirsutism, acne 
and/or alopecia, menstrual irregularity and polycystic 
ovaries. It is not only a reproductive endocrinopathy 
but also a metabolic disorder.[1,2] 
The exact prevalence of PCOS is not known as the 
syndrome has not been precisely defined. The 
estimated prevalence in women of reproductive age is 
5-10%.[3]The pathophysiology is complex involving the 
hypothalamus-pituitary-ovarian axis, ovarian theca cell 
hyperplasia, hyperinsulinemia and a multitude of other 
cytokine and adipocyte-driven factors.[4] 
Women with PCOS share many features in common 
with the metabolic syndrome[1] and It is also associated 
with an increased risk for metabolic complications like 
insulin resistance (IR) with consequent compensatory 
hyperinsulinaemia, dyslipidaemia and cosmetic 
problems.[5]One of the most prominent metabolic 
symptoms of PCOS is insulin resistance, which includes 
hyperinsulinaemia and impaired glucose tolerance.They 
also develop abnormal glucose metabolism at a 
younger age and may demonstrate a more rapid 
conversion from impaired glucose tolerance to type2 
diabetes mellitus.[6]Impaired glucose tolerance and 
diabetes are not only known risk factors for 
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cardiovascular disease but also present with their own 
morbidity.  
Obesity increases hyperandrogenism, hirsutism, 
infertility and pregnancy complications both 
independently and by exacerbating PCOS. Likewise, in 
PCOS obesity worsens insulin resistance and 
exacerbates reproductive and metabolic 
features.[7]Adiposity plays a vital role in the 
development and maintenance of PCOS and it strongly 
influences the severity of both its clinical and endocrine 
features. In addition to abnormal distribution of 
adipose tissue in women with PCOS, there may also be 
inherent abnormalities of   lipolysis within adipocytes 
that are site specific[8]. Women with PCOS have 
disturbed lipid profiles. The causes of dyslipidaemia in 
PCOS are again multifactorial. Insulin Resistance 
appears to have a important role; mediated in part by 
stimulation of   lipolysis and altered expression of 
lipoprotein lipase and hepatic lipase.[9] 
IR and dyslipidemia seem to have an important role on 
the risk of cardiovascular pathology in women with 
PCOS. It is still not known to what degree dyslipidemia 
contributes to this risk.[10] 
PCOS may represent the largest under-appreciated 
segment of the female population at risk of Type2 
Diabetes Mellitus and cardiovascular disease. So, it is 
recommended that women with PCOS be routinely 
screened for indicators of early metabolic changes in 
order to anticipate early diagnosis and management. In 
view of this, the present study was undertaken to 
estimate and correlate the fasting blood sugar levels 
and lipid profile that may help to identify women with 
PCOS at risk of Cardiometabolic syndrome.     
MATERIAL AND METHODOLOGY 
The observational case-control study was conducted at 
Raichur institute of medical sciences teaching Hospital, 
and OPEC super specialty Hospital Raichur from 
September 2014-September 2015. Study consists of 50 
female patients newly diagnosed with PCOS based on 
Rotterdam criteria in the age group of 18-40 years as 
cases and 50 age matched healthy female volunteers 
with regular menstrual cycles and with no clinical 
evidence of hyperandrogenism or PCOS were taken as 
control subjects. Institutional ethical committee 
approved the study and informed consent obtained 
from all the study subjects. All subjects answered a 
questionnaire which contained details of age, 
menstrual history, medical history and family history of 
type2 diabetes mellitus or polycystic ovarian syndrome.  
Inclusion criteria:  
Cases: Female patients newly diagnosed with PCOS 
based on Rotterdam Criteria, in the age group of 18-40 
years. 
Women with oligomenorrhoea/Amenorrhoea, 
clinical/Biochemical signs of hyperandrogenism 
(including: Hirsutism, Acne, Alopecia etc.), elevated 
androgen levels, Presence of Polycystic ovaries on USG 
were included in the study. 
Controls:  Age matched healthy female volunteers with 
regular menstrual cycles and no signs of clinical 
hyperandrogenism or PCOS. 
Exclusion criteria:  
Women with Diabetes mellitus, hypertension, thyroid 
disorders, renal diseases, cardiovascular diseases, 
cushing syndrome, pregnant/lactating women, women 
on drugs (oral contraceptives, hypoglycemic agents/ 
lipid lowering drugs), hormonal medicines within 6 
weeks were excluded from the study.  
Method of collection of data:  
A pre-structured and pretested proforma was used to 
collect the data. Baseline data including age, BMI, 
detailed medical history, family history, clinical 
examinations were included as part of the 
methodology. 
Anthropometric data: 
Body Mass Index: 
All the subjects’ height and weight were recorded using 
standard apparatus. 
Body mass index (BMI) was calculated by dividing 
weight (kg) by height (m2).  
Normal weight was defined as BMI < 25, Overweight as 
BMI between 25.0-29.9 and Obesity as BMI > 30. 
Waist circumference and waist:hip ratio  
Waist circumference was measured mid-way between 
the last palpable rib and the top part of the iliac crest 
and the hip circumference was taken around the widest 
portion of the buttocks. 
Blood Pressure: 
Blood Pressure was measured in the right arm, with the 
subjects in a relaxed sitting position using a mercury 
sphygmomanometer. 
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Sample Collection and Storage: 
5 ml of venous blood samples was collected from 
healthy controls and women with PCOS after 12 hrs 
overnight fast. 1 ml of sample was taken in a tube 
containing anticoagulant and analysed for plasma 
glucose. 4 ml of sample was taken in a plain tube. After 
centrifugation at 3000 rpm for 10 minutes, the serum 
samples were incubated for 15 minutes at room 
temperature and analysed.  
Biochemical Method: 
Lipid Profile using standard kits (ERBA: Glucose,Total-
Cholesterol, Triglycerides, High Density Lipoprotein-
Cholesterol [HDL-C]) in Semi- Auto analyser (Mannheim 
Erba chem5X) either on the same day of collection or 
stored at 2-80C until further analysis.  
I. Plasma glucose was analysed by Glucose Oxidase-
Peroxidase Method 
II. Serum sample was used for following biochemical 
assays: 
Lipid Profile:  
Total Cholesterol (Cholesterol Oxidase Method);  
Triglycerides (Glycerol Phosphate Oxidase and 
Peroxidase Method);  
High Density Lipoprotein Cholesterol (Phosphotungstic 
Acid Method);  
LDL-C and VLDL-C were calculated using the 
Friedewald’s formula: 
LDL Cholesterol = [Total cholesterol] - [HDL cholesterol] 
[TRIGLYCERIDE]/5; 
VLDL Cholesterol = [Triglyceride]/5 (Where all 
concentrations are given in mgs/dl) 
Statistical Analysis: Data Analysis was performed using 
SPSS 16 Software. The values were expressed as mean ± 
Standard Deviation. Deviation and the findings were 
analysed by student “t” test. Pearson's correlation 
coefficients were calculated to assess the correlation 
between the biochemical parameters in the study 
group. A 'P' value of < 0.05 was considered statistically 
significant. 
RESULTS 
Table I shows the mean, standard deviation and P 
values of anthropometric measurement, FBS and Lipid 
profile in PCOS patients and controls. The mean age of 
the PCOS group and the control group were not 
statistically significant. PCOS patients had significantly 
high BMI (p < 0.01), waist circumference (p<0.001), 
Systolic Blood Pressure (P<0.001) and diastolic blood 
pressure (P < 0.001) as compared to controls. 
The PCOS group showed a significantly higher fasting 
glucose (P < 0.001). PCOS patients had increased total 
cholesterol, triglycerides, LDL-C, VLDL-C and decreased 
HDL-C as compared to the controls which were 
statistically significant. 
Table ІІ: shows correlation between various parameters 
in PCOS cases. From the table it can be inferred that 
BMI (kg/m2) has significant positive correlation with 
Fasting blood glucose, total cholesterol, triglyceride, 
LDL-c and VLDL-c where as significant negative 
correlation with HDL-c. From the table ІІІ it can be 
inferred that Fasting blood sugar level has significant 
positive correlation with serum total cholesterol, serum 
triglyceride, serum LDL-c and serum VLDL-c whereas 
non significant negative correlation with serum HDL-c. 
Table 1. Mean, Standard Deviation and P Values of 
Anthropometric Measurements, Fasting blood sugar and 
Lipid profile in PCOS Patients and Control Groups. 
Parameter Cases (n=50) Controls(n=50) 
P 
value 
Age (yrs) 
 
BMI (Kg/m2) 
 
Waist 
circumference 
(cm) 
 
Waist Hip ratio 
 
SBP (mm Hg) 
 
DBP (mmHg) 
 
FBS (mg/dl) 
 
Total cholesterol 
(mg/dl) 
 
Triglyceride 
(mg/dl) 
 
HDL-c (mg/dl) 
 
LDL-c (mg/dl) 
 
VLDL-c (mg/dl) 
 
  26.16± 3.77 
 
  27.50± 2.54 
 
   
85.47± 5.46 
 
 
 0.786± 0.055 
 
  118.48±8.79 
 
  78.92±5.47 
 
  97.62± 7.19 
 
187.44±25.08 
 
 
138.3± 40.32 
 
  
40.64± 8.87 
 
120.17± 28.17 
 
 27.61± 8.91 
  27.38± 5.01 
 
  25.9± 2.21 
 
   
78.2±4.34 
 
 
 0.7384±0.05 
 
   110.96±5.92 
 
  74.52±4.19 
 
  90.28± 8.52 
 
  165.52± 19.21 
 
 
104.69± 32.88  
 
  
 45.78± 5.86 
 
98.79± 19.45   
 
  20.93±6.57  
>0.05 
 
<0.01 
 
 
<0.001 
 
 
>0.05 
 
<0.001 
 
<0.001 
 
<0.001 
 
<0.001 
 
 
<0.01 
 
 
<0.05 
 
<0.001   
 
<0.01 
 
P value of <0.05 considered statistically significant 
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Table 2. correlation of BMI with other parameters in PCOS 
P value of <0.05 considered statistically significant 
Table 3. Correlation of Glucose and Lipid profile in PCOS 
Parameter 
 
         Glucose (mg/dl) 
     r                      p 
Total cholesterol 
Triglyceride  
HDL-c 
LDL-c 
VLDL-c 
0.740                <0.01 
0.377                <0.05 
-0.251               >0.05 
0.699                <0.01 
0.321                <0.05 
P value of <0.05 considered statistically significant 
DISCUSSION  
Considerable evidence has accumulated for the 
coexistence of the metabolic syndrome and PCOS. A 
key alteration in the former appears to be insulin 
resistance which is associated with an increased 
morbidity and mortality due to coronary artery disease 
with its enormous public health implications. It has 
been suggested that inherited defects leading to 
peripheral insulin resistance and concurrent 
hyperinsulinaemia are among the causative factors for 
the development of PCOS. However, due to the 
heterogeneity of PCOS, it is unclear whether all subjects 
with this disease are equally susceptible to the 
symptoms and sequelae of the metabolic syndrome. All 
in all, the possibility of an increased risk of coronary 
artery disease in women with PCOS warrants effective 
diagnostics of the syndrome. Known susceptibility to 
coronary heart disease should also be kept in mind 
when designing hormonal therapies for PCOS patients. 
Clinical manifestations of the metabolic syndrome, i.e. 
coronary artery disease and diabetes mellitus, have 
caused it to be referred to as the 'secret killer'. As 
preventive measures can slow down the appearance of 
these late symptoms, it is important to recognize at-risk 
populations during the symptomless period[11]. Cardio 
metabolic syndrome is a clustering of inter related risk 
factors that promote the development of 
atherosclerotic vascular disease and Type 2 DM. These 
interrelated risk factors have direct effect on 
atherogenic Dyslipidaemia, elevated blood pressure, 
and elevated plasma glucose, and promote 
proinflammatory and prothrombotic states.[12] 
Obesity is defined as BMI of > 30 and overweight as 
BMI of 25-29.9. PCOS patients display central or 
abdominal or android obesity, which is characterized by 
an increased waist-hip ratio. This visceral distribution of 
adipose tissue can be inferred clinically by a waist-hip 
ratio of more than 0.85.In our study the mean BMI in 
normal healthy women (controls) is 25.9±2.21(kg/m2) 
and in PCOS women (cases)  is 27.50±2.54(kg/m2). The 
mean BMI was higher in PCOS cases than controls and 
the mean difference was statistically significant 
(P<0.01). This is in accordance with other study which 
showed that excess visceral fat seems to be predictive 
not only of the metabolic syndrome but also of CVD. A 
person’s waist circumference is the simplest way to 
assess central obesity. Waist circumference has been 
shown to be one of the most accurate 
anthropometrical indicators of abdominal fat.[13]Waist 
circumference≥80 cm in women is considered as a 
positive indicator of abdominal obesity as per the 
consensus India guidelines for Indian population.[14] In  
our study mean waist circumference for normal healthy 
women (controls) is 78.2±4.34 cm and in PCOS 
women(cases) is 85.47±5.46 cm and there was highly 
significant statistical difference in the mean waist 
circumference values (P<0.001). In the present study 
the mean waist hip ratio for normal healthy women 
(controls) is 0.7384±0.033 and in PCOS women (cases) 
is 0.786±0.0551. The mean waist hip ratio was higher in 
cases than controls and the mean difference was not 
statistically significant. 
In our study mean systolic blood pressure in normal 
healthy women (controls) is 110.96±5.992 mmHg and in 
PCOS women(cases) it is 118.48±8.795 mmHg. The 
mean diastolic blood pressure in controls is 74.52±4.19 
mmHg and in cases it is 78.92±5.473 mmHg. There is 
highly significant statistical difference in the mean 
blood pressure values (P<0.001). 
Parameter         BMI(kg/m2) 
    r                   p 
Glucose  
Total cholesterol 
Triglyceride  
HDL-c 
LDL-c 
VLDL-c 
0.687          <0.01 
0.691          <0.01 
0.568           <0.01 
-0.391          <0.05 
0.607           <0.01 
0.498           <0.01 
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Impaired glucose tolerance (IGT) AND impaired fasting 
glucose (IFG) are now referred to as “pre-diabetic” 
indicating the relatively high risk for development of 
diabetes in these persons. In the absence of pregnancy, 
IFG and IGT are not clinical entities in their own right 
but rather risk factors for future diabetes as well as 
cardiovascular diseases.[15 
The results of our study showed mean fasting blood 
glucose in normal healthy women (controls) as 
90.28±8.52 mg/dl and in PCOS women (cases) it was 
97.92±7.196 mg/dl. There was very highly significant 
statistical difference in the mean fasting blood glucose 
values (P<0.001). Our study also showed significant 
positive correlation between fasting blood glucose and 
BMI, TG and VLDL-c (P<0.05) and high significant 
positive correlation with, TC and LDL-c (P<0.01) 
whereas non significant negative correlation with HDL-c 
(P>0.05). 
V.M. Vinodhini et al., showed no statistically significant 
differences in the mean concentrations of fasting 
plasma glucose between PCOS patients and healthy 
controls[16] whereas, a study by Azevedo MF et al., 
reported higher fasting glucose levels in PCOS women 
which was statistically significant.[17]Our result was 
consistent with the study of Azevedo MF et al.,. Our 
study is consistant with the other  study conducted 
among 30 pre-menopausal women and 30 healthy 
controls, increased fasting glucose levels and decreased 
magnesium levels were noted in women with PCOS as 
compared to controls and the differences noted were 
statistically significant.[3]In another study, impaired 
glucose tolerance (IGT), fasting insulin and Homeostasis 
Model Assessment of IR (HOMA-IR) were found to be 
significantly higher in the study group, when compared 
to the healthy controls.[18]In a study conducted among 
28 PCOS patients and 24 control women who were 
divided into obese and non-obese groups, 75% of the 
PCOS subjects presented with insulin resistance 
suggesting that insulin resistance not only depends on 
the BMI but also on the presence of PCOS.[19] 
Obesity is known to have a strong influence on the 
prevalence of several metabolic abnormalities in 
women with PCOS. The syndrome may be associated 
with a change in both lipid and lipoprotein metabolism 
(a more atherogenetic lipoprotein pattern is seen in the 
presence of obesity). Increase in the triglycerides and 
total cholesterol levels and a greater reduction of high-
density lipoproteins (HDLs) have been observed in 
obese women with PCOS.[20]Our study showed highly 
significant statistical difference in the mean values of 
TC, TG, LDL-c and VLDL-c in PCOS cases than controls, 
the mean values being higher in cases than controls 
where as mean HDL-c values were lower in PCOS cases 
than controls and the difference was statistically 
significant. This is in agreement with the other study 
which show that there is an elevation of triglycerides, 
cholesterol and LDL-C in combination with decreased 
HDL-C and apoA-I.3.  
Our study found that HDL-C is lower in PCOS group than 
in control group whereas higher mean VLDL was seen in 
PCOS compared to controls. This is consistent with the 
other study who showed that women with PCOS had 
higher triglycerides and VLDL-C with lower HDL2-C and 
apolipoprotein A1:A2 ratios.[21] 
Another study compared lean and obese PCOS with 
control subjects. They also found lower levels of HDL2 
cholesterol and higher levels of apolipoprotein B in 
PCOS. Obese women had lower levels of HDL-C and 
apoA-I with higher triglycerides and VLDL-C.[22]A study 
by AnuradhaKalra et al., found no correlation between 
BMI with various lipid parameters.[2] But in our 
investigation, we found a significant positive correlation 
between BMI and total cholesterol, triglycerides, LDL-C, 
VLDL-C and significant negative correlation between 
BMI and HDL-C.  Our study is in agreement with the 
another study where the total serum cholesterol, 
triglycerides, LDL cholesterol (LDL-C) and Very Low-
density lipoprotein cholesterol(VLDL-C) were higher in 
the women with PCOS and higher BMI. Significantly 
lower levels of serum HDL-C were also noted. Positive 
correlations were observed between: uric acid and HDL-
C, glucose and total cholesterol, triglycerides, LDL-C, 
and VLDL-C.[3] 
Our study showed that PCOS women had higher BMI, 
significantly increased total cholesterol, triglycerides, 
LDL-C and VLDL-C. On the other hand, serum levels of 
HDL-C were significantly lower in this group compared 
to controls. 
CONCLUSION 
The use of these simple biochemical parameters might 
prove to be biomarkers in early detection of these 
metabolic changes and may help to identify women 
with PCOS at risk of cardio metabolic syndrome. Based 
on early recognition of PCOS, efforts may be done to 
limit or forestall the onset or progression of clinical 
symptomatology. In addition, treatment may be 
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instituted in an attempt to prevent or restrict the long-
term complications of PCOS namely diabetes and its 
related complications, including cardiovascular disease. 
However future prospective studies needed in this 
aspect. Currently the most effective modalities appear 
to be life-style modification and ovarian suppression by 
oral contraceptives. 
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